Phase I/II study of PCI-27483, a coagulation factor VIIa (FVIIa) inhibitor, in combination with gemcitabine in patients with advanced pancreatic cancer.

Sameer A. Mahesh,Nashat Y. Gabrail,Jitendra G. Gandhi,Alok A. Khorana,Robert Manges,Satish Shah,Gary Thomas,Ahmed Hamdy,Michelle Stevens-Brogan,Cathy Zhou,Laurence Elias,David Loury,Ramesh K. Ramanathan

Phase I/II study of PCI-27483, a coagulation factor VIIa (FVIIa) inhibitor, in combination with gemcitabine in patients with advanced pancreatic cancer.

2013

Sameer A. Mahesh
Nashat Y. Gabrail
Jitendra G. Gandhi
Alok A. Khorana
Robert Manges
Satish Shah
Gary Thomas
Ahmed Hamdy
Michelle Stevens-Brogan
Cathy Zhou
Laurence Elias
David Loury
Ramesh K. Ramanathan

e15014 Background: Tissue factor (TF) up-regulation is associated with increased tumor invasiveness and progression, worsened prognosis and increased thromboembolism (VTE). Activation of protease a...

Keywords:

Pancreatic cancer
Gemcitabine
Cancer research
Conventional PCI
Coagulation factor VIIa
Medicine
Protease
Pathology
phase i ii
in patient
Tissue factor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations